Literature DB >> 19961478

Ribosome-associated nucleophosmin 1: increased expression and shuttling activity distinguishes prognostic subtypes in chronic lymphocytic leukaemia.

Karen S Rees-Unwin1, Robin Faragher, Richard D Unwin, Julie Adams, Philip J Brown, Ann-Marie Buckle, Andrew Pettitt, Claire V Hutchinson, Suzanne M Johnson, Karen Pulford, Alison H Banham, Anthony D Whetton, Guy Lucas, David Y Mason, John Burthem.   

Abstract

Two distinct groups of chronic lymphocytic leukaemia (CLL) are distinguished by the presence or absence of somatic hypermutation of the immunoglobulin heavy-chain gene. CLL without somatic hypermutation has an adverse outcome, but the precise biological differences that underlie this more aggressive clinical-course are unclear. Using a proteomic approach, we found that the two prognostic forms of CLL were consistently distinguished according to their protein expression pattern. The most important difference observed related to the different expression of nucleophosmin 1 between the two forms of CLL. This different expression was not related to apoptosis, proliferation or gene mutation. However, co-immunoprecipitation experiments identified an association between nucleophosmin 1 and ribosomal proteins. Using immunocytofluorescence, nucleophosmin 1 expression was identified in the nucleoli and nucleoplasm of all cells, but in a proportion of cells, nucleophosmin had been transferred from the nucleoplasm to the cytoplasm. Both the fluorescent intensity, and the frequency of cytoplasmic nucleophosmin 1 expression, was higher in CLL without somatic hypermutation. We propose therefore, that nucleophosmin 1, in association with ribosomal proteins, undergoes nucleo-cytoplasmic shuttling in CLL. This process is most prominent in un-mutated CLL and may signify altered protein biosynthesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19961478     DOI: 10.1111/j.1365-2141.2009.07979.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Structural polymorphism in the N-terminal oligomerization domain of NPM1.

Authors:  Diana M Mitrea; Christy R Grace; Marija Buljan; Mi-Kyung Yun; Nicholas J Pytel; John Satumba; Amanda Nourse; Cheon-Gil Park; M Madan Babu; Stephen W White; Richard W Kriwacki
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-10       Impact factor: 11.205

2.  Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation.

Authors:  Harvey E Johnston; Matthew J Carter; Marta Larrayoz; James Clarke; Spiro D Garbis; David Oscier; Jonathan C Strefford; Andrew J Steele; Renata Walewska; Mark S Cragg
Journal:  Mol Cell Proteomics       Date:  2018-01-24       Impact factor: 5.911

3.  Down-regulated expression of NPM1 in IMS-M2 cell line by (-)-epigallocatechin-3-gallate.

Authors:  Hoang Thanh Chi; Bui Thi Kim Ly; Hoang Anh Vu; Yuko Sato; Phu Chi Dung; Phan Thi Xinh
Journal:  Asian Pac J Trop Biomed       Date:  2014-07

4.  NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.

Authors:  F Pozzo; T Bittolo; E Vendramini; R Bomben; P Bulian; F M Rossi; A Zucchetto; E Tissino; M Degan; G D'Arena; F Di Raimondo; F Zaja; G Pozzato; D Rossi; G Gaidano; G Del Poeta; V Gattei; M Dal Bo
Journal:  Leukemia       Date:  2017-03-21       Impact factor: 11.528

5.  Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.

Authors:  Gina L Eagle; Jianguo Zhuang; Rosalind E Jenkins; Kathleen J Till; Puthen V Jithesh; Ke Lin; Gillian G Johnson; Melanie Oates; Kevin Park; Neil R Kitteringham; Andrew R Pettitt
Journal:  Mol Cell Proteomics       Date:  2015-02-02       Impact factor: 5.911

6.  A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment.

Authors:  T Sbarrato; E Horvilleur; T Pöyry; K Hill; L C Chaplin; R V Spriggs; M Stoneley; L Wilson; S Jayne; T Vulliamy; D Beck; I Dokal; M J S Dyer; A M Yeomans; G Packham; M Bushell; S D Wagner; A E Willis
Journal:  Cell Death Dis       Date:  2016-06-02       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.